Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Shares Sold by Penserra Capital Management LLC

Penserra Capital Management LLC reduced its stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 77.6% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 11,584 shares of the company's stock after selling 40,059 shares during the quarter. Penserra Capital Management LLC's holdings in Teva Pharmaceutical Industries were worth $178,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in TEVA. Charles Schwab Investment Management Inc. increased its stake in Teva Pharmaceutical Industries by 14.4% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,028,924 shares of the company's stock worth $22,677,000 after acquiring an additional 129,749 shares during the last quarter. Assetmark Inc. grew its stake in shares of Teva Pharmaceutical Industries by 1,370.3% during the fourth quarter. Assetmark Inc. now owns 5,205 shares of the company's stock valued at $115,000 after buying an additional 4,851 shares during the last quarter. Daiwa Securities Group Inc. grew its stake in shares of Teva Pharmaceutical Industries by 3.9% during the fourth quarter. Daiwa Securities Group Inc. now owns 92,965 shares of the company's stock valued at $2,049,000 after buying an additional 3,500 shares during the last quarter. HighTower Advisors LLC grew its stake in shares of Teva Pharmaceutical Industries by 32.3% during the fourth quarter. HighTower Advisors LLC now owns 196,657 shares of the company's stock valued at $4,334,000 after buying an additional 48,052 shares during the last quarter. Finally, Sequoia Financial Advisors LLC grew its stake in shares of Teva Pharmaceutical Industries by 1.3% during the fourth quarter. Sequoia Financial Advisors LLC now owns 113,797 shares of the company's stock valued at $2,508,000 after buying an additional 1,417 shares during the last quarter. 54.05% of the stock is owned by institutional investors.

Teva Pharmaceutical Industries Stock Up 1.1%

Shares of NYSE TEVA traded up $0.18 during trading hours on Monday, hitting $16.58. 1,900,856 shares of the stock were exchanged, compared to its average volume of 10,242,582. The company has a quick ratio of 0.74, a current ratio of 1.03 and a debt-to-equity ratio of 2.59. The company has a market cap of $19.01 billion, a PE ratio of -14.41, a PEG ratio of 0.84 and a beta of 0.60. The firm has a fifty day moving average price of $17.09 and a 200-day moving average price of $17.12. Teva Pharmaceutical Industries Ltd. has a 12 month low of $12.47 and a 12 month high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The company reported $0.52 EPS for the quarter, beating the consensus estimate of $0.47 by $0.05. Teva Pharmaceutical Industries had a positive return on equity of 45.44% and a negative net margin of 7.74%. The firm had revenue of $3.89 billion during the quarter, compared to analyst estimates of $3.99 billion. During the same quarter in the prior year, the business posted $0.48 EPS. The business's revenue for the quarter was up 1.9% compared to the same quarter last year. On average, sell-side analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current year.

Insider Transactions at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, EVP Matthew Shields sold 6,206 shares of Teva Pharmaceutical Industries stock in a transaction dated Tuesday, June 3rd. The stock was sold at an average price of $17.02, for a total transaction of $105,626.12. Following the completion of the transaction, the executive vice president owned 9,989 shares in the company, valued at approximately $170,012.78. This trade represents a 38.32% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 0.55% of the stock is owned by company insiders.

Analyst Ratings Changes

TEVA has been the topic of a number of analyst reports. JPMorgan Chase & Co. raised Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and upped their target price for the company from $21.00 to $23.00 in a research note on Monday, May 12th. Hsbc Global Res raised shares of Teva Pharmaceutical Industries to a "strong-buy" rating in a research report on Monday, April 28th. Bank of America boosted their price objective on shares of Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the company a "buy" rating in a research report on Thursday, May 8th. Wall Street Zen raised shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research report on Thursday, May 22nd. Finally, Truist Financial began coverage on Teva Pharmaceutical Industries in a research note on Wednesday, May 28th. They issued a "buy" rating and a $25.00 price objective on the stock. Seven investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $24.71.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.